Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Cost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Lifecore Biomedical, Inc. \De\ (LFCR) Research & Development (2016 - 2025)

Historic Research & Development for Lifecore Biomedical, Inc. \De\ (LFCR) over the last 17 years, with Q2 2025 value amounting to $2.1 million.

  • Lifecore Biomedical, Inc. \De\'s Research & Development fell 268.39% to $2.1 million in Q2 2025 from the same period last year, while for May 2025 it was $8.3 million, marking a year-over-year decrease of 369.68%. This contributed to the annual value of $8.3 million for FY2025, which is 369.68% down from last year.
  • Per Lifecore Biomedical, Inc. \De\'s latest filing, its Research & Development stood at $2.1 million for Q2 2025, which was down 268.39% from $2.0 million recorded in Q1 2025.
  • Lifecore Biomedical, Inc. \De\'s Research & Development's 5-year high stood at $2.3 million during Q1 2022, with a 5-year trough of $1.6 million in Q1 2021.
  • In the last 5 years, Lifecore Biomedical, Inc. \De\'s Research & Development had a median value of $2.1 million in 2023 and averaged $2.0 million.
  • Data for Lifecore Biomedical, Inc. \De\'s Research & Development shows a peak YoY increase of 31250.0% (in 2021) and a maximum YoY decrease of 4040.77% (in 2021) over the last 5 years.
  • Quarter analysis of 5 years shows Lifecore Biomedical, Inc. \De\'s Research & Development stood at $1.7 million in 2021, then increased by 29.58% to $2.2 million in 2022, then fell by 3.63% to $2.1 million in 2023, then fell by 8.29% to $1.9 million in 2024, then grew by 9.3% to $2.1 million in 2025.
  • Its Research & Development was $2.1 million in Q2 2025, compared to $2.0 million in Q1 2025 and $1.9 million in Q4 2024.